A preclinical trial of the reassortant influenza virus vaccinе strain A/17/Quail/Hong Kong/97/84 (H9N2)

Cover Page

Cite item

Full Text

Abstract

In this work, we examined the reassortant influenza virus strain A/17/Quail/Hong Kong/97/84 (H9N2) prepared at the Virology Department, Institute of Experimental Medicine, Russian Academy of Medical Sciences. The A/Leningrad/134/17 (H2N2)-based vaccine candidate contained hemagglutinin and the neuraminidase from the nonpathogenic avian influenza A virus A(H9N2) of the G1 antigenic lineage. The vaccine candidate showed the ts-properties and cold adaptation. When administered intranasally to mice, the vaccine strain A(H9N2) was attenuated. It did not multiply in the lungs but was reproduced well in the nasal cavity, causing the production of the post-vaccination antibody. The A/17/Quail/Hong Kong/97/84(H9N2) virus was immunogenic when administered to mice as a LAI V intranasally or as a IIV intramuscularly. Intranasal A(H9N2) LAIV stimulated ocal production of the antibodies, which resulted in reduction in lung titers of the challenge virus G9.

About the authors

Yu. A. Desheva

Institute of Experimental Medicine

Author for correspondence.
Email: desheva@mail.ru

Yuliya Desheva, MD,PhD, DSc

197376, St. Petersburg

Russian Federation

T. A. Smolonogina

Institute of Experimental Medicine

Email: fake@neicon.ru
197376, St. Petersburg Russian Federation

L. G. Rudenko

Institute of Experimental Medicine

Email: fake@neicon.ru
197376, St. Petersburg Russian Federation

References

  1. Каверин Н.В., Смирнов Ю.А. Межвидовая трансмиссия вирусов гриппа А и проблема пандемий. Вопросы вирусологии. 2003; 48(3): 4–10.
  2. Wang M., Fu C.X., Zheng B.J. Antibodies against H5 and H9 avian influenza among poultry workers in China. N. Engl. J. Med. 2009; 360(24): 2583–4.
  3. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W. et al. Human infection with inluenza H9N2. Lancet. 1999; 354: 916–7.
  4. Saito T., Lim W., Suzuki T., Suzuki Y., Kida H., Nishimura S.I. et al. Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine. 2001; 20(1–2): 125–33.
  5. Guan Y., Shortridge K.F., Krauss S., Chin P.S., Dyrting K.C., Ellis T. et al. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China. J. Virol. 2000; 74(20): 9372–80.
  6. Jiang W., Liu S., Hou G., Li J., Zhuang Q., Wang S. et al. Chinese and global distribution of H9 subtype avian influenza viruses. PLoS One. 2012; 7(12):e52671.
  7. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness – February 2011. Wkly Epidemiol. Rec. 2011; 86(11): 93–100. Available at: http://www.who.int/wer/2011/wer8611.pdf
  8. Rudenko L., Kiseleva I., Mironov A., Desheva J., Larionova N., Chirkova T. et al. Development of pandemic live attenuated influenza vaccine (LAIV) in Russia. Influenza Other Respir. Viruses. 2011; 5(Suppl. 3): 333–7.
  9. Дешева Ю.А., Смолоногина Т.А., Сергеева М.В., Рекстин А.Р., Свэйн Д., Климов А.И. и др. Изучение биологических свойств холодоадаптированного реассортантного штамма вируса гриппа подтипа H7N3. Журнал микробиологии, эпидемиологии и иммунологии. 2009; 1: 31–6.
  10. Дешева Ю.А., Руденко Л.Г., Александрова Г.И., Смолоногина Т.А. Штамм вируса гриппа для производства живой и инактивированной гриппозной вакцины. Патент РФ № 2464309, 2012.
  11. Shirvan A.N., Moradi M., Aminian M., Madani R. Preparation of neuraminidase-specific antiserum from the H9N2 subtype of avian influenza virus. Turk. J. Vet. Anim. Sci. 2007; 31(4): 219–23.
  12. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W. et al. Detection of antibody to avian influenza A(H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 1999; 37(4): 937–43.
  13. Lu X., Renshaw M., Tumpey T.M., Kelly G.D., Hu-Primmer J., Katz J. M. Immunity to influenza A H9N2 viruses induced by infection and vaccination. J. Virol. 2001; 75: 4896–901.
  14. Johnson P. R., Feldman S., Thompson J. M., Mahoney J. D., Wright P. F. Immunity to infuenza A virus infection in young children: a comparison of natural infection, live cold-adapted and inactivated vaccines. J. Infect. Dis. 1986; 154: 121–6.
  15. Rudenko L.G., Arden N. H., Grigorieva E., Naychin A., Rekstin A., Klimov A. et al. Immunogenicity and efficacy of Russian live attenuated and U.S. inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine. 2001; 19: 308–18
  16. Stephenson I., Nicholson K.G., Glück R., Mischler R., Newman R.W., Palache A. M. et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99(H9N2) vaccine in healthy adults: phase I randomized trial. Lancet. 2003; 362: 1959–66.
  17. Chen H., Subbarao K., Swayne D., Chen Q., Lu X., Katz J. et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine. 2003; 21:1974–9.
  18. Karron R.A., Callahan K., Luke C., Thumar B., Mc Auliffe J., Schappell E. et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J. Infect. Dis. 2009; 199(5): 711–6.
  19. Todd S., de Bruin E., Nhat N.T., Koopmans M., Boni M.F. Potential for H9-positive serological signals in humans due to cross-reactivity among influenza subtypes. J. Infect. Dis. 2014; 210(1) 161–3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Desheva Y.A., Smolonogina T.A., Rudenko L.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies